Pharmaceuticals, Biotechnology and Life Sciences
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Adtralza tralokinumab in a new pre-filled pen, following the European Commission (EU) decision on the 1st of September 2023. The pre-filled pen will be available in the UK for tralokinumab patients from early 2024.
LEO Pharma shared results showing that after two years of continuous treatment with Adtralza, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference
LEO Pharma UK said that the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission (EC) has approved tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
The European Commission regulatory approval is primarily supported by data from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase…
BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes…
Leo Pharma on Monday presented new results from the PSO-LONG clinical trial, the first to provide long-term maintenance data for…
— Data include pivotal efficacy and safety clinical trials of tralokinumab monotherapy and tralokinumab with concomitant topical corticosteroid use in…
Ubiquigent and LEO Pharma A/S have entered into an option agreement granting LEO Pharma access to two novel compounds, which comes after an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation, without disclosing financial terms.
Unified applications for clinical, regulatory, and quality streamline end-to-end product development to increase operational efficiency BARCELONA, Spain–(BUSINESS WIRE)–Veeva Systems (NYSE:VEEV) today…
ANDERNACH, Germany & BALLERUP, Denmark–(BUSINESS WIRE)–LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma…